

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/006893 A1

(43) International Publication Date
02 February 2023 (02.02.2023)

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 498/04 (2006.01)
C07D 403/06 (2006.01) C07D 513/04 (2006.01)
C07D 403/12 (2006.01) A61P 29/00 (2006.01)
C07D 417/04 (2006.01) A61K 31/496 (2006.01)
C07D 417/06 (2006.01) A61K 31/497 (2006.01)
C07D 417/12 (2006.01) A61K 31/517 (2006.01)
C07D 417/14 (2006.01) A61K 31/551 (2006.01)
C07D 487/04 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/EP2022/071231

(22) International Filing Date:

28 July 2022 (28.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/227,552 30 July 2021 (30.07.2021) US
63/227,555 30 July 2021 (30.07.2021) US

(71) Applicant: **CONFO THERAPEUTICS N.V.** [BE/BE];
Technologiepark 94, 9052 Gent-Zwijnaarde (BE).

(72) Inventors: **DE BLIECK, Ann**; Vleeshouwersstraat 74,
9112 Sinaai (BE). **MENET, Christel Jeanne Marie**; 7, Rue
de Lausanne, 1060 Brussels (BE).

(74) Agent: **NEDERLANDSCH OCTROOIBUREAU**;
P.O.Box 29720, 2502 LS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING

(57) Abstract: The present invention relates to compounds that can be used for the prevention, treatment and/or management of pain, in particular chronic pain, such as neuropathic pain, and/or other diseases or disorders that are associated with AT2R and/or AT2R-mediated signaling.

WO 2023/006893 A1